Successful Completion $15M Placement
Released
Released
Announcement PDF
ASX RELEASE
28TH MAY 2026
SUCCESSFUL $15 MILLION PLACEMENT AND
ANNOUNCEMENT OF SHARE PURCHASE PLAN
1
Highlights
Tetratherix Limited (ASX:TTX) (Tetratherix) has received firm commitments from new and existing
institutional investors for a Placement to raise $15M (before costs) (Placement).
The Placement was conducted at $6 per share, a 2% discount to the 10-day VWAP.
SPP offer to be made to existing eligible shareholders to raise up to a further $2M.
Proceeds from the Placement and SPP will be used to fund production expansion, strategic partnerships,
customer success, digitalisation, working capital and transaction costs.
Will Knox CEO commented:
"This $15 million capital injection, backed by exceptional demand from both existing and new institutional
partners, is a definitive validation of Tetratherix’s technical, commercial and organisational advantages. The
market has recognised the compounding value of our Tetramatrix polymer platform, attracting world class
investors. We are scaling a highly integrated, increasingly digitalised, and fundamentally unique medical
technology platform.
TM
This capital further secures a fully funded, exciting runway as we rapidly transition to commercialisation in 2026. It
allows us to immediately supercharge our production mechanics, expand our strategic partnership ecosystem,
and embed comprehensive customer success infrastructure to capture global market share with our partners.
Over the past 12 months, our industry leading team has demonstrated relentless operational execution by
consistently hitting our commercial, clinical and development milestones. We enter this next chapter with
immense momentum as we aggressively commercialise our platform to deliver value."
Details of the Placement
The Placement to sophisticated and professional investors will raise gross proceeds of $15M from a two-tranche
issue of new fully paid ordinary shares (Placement Shares). The issue price of $6 represents a 2% discount to
the 10-day Volume Weighted Average Price (VWAP) of $6.12. Placement Shares will rank equally with existing
shares of Tetratherix from their issue date. Placement Tranche 1 shares, shares issued to new and existing
institutional investors, are anticipated to settle on 3 June 2026. Placement Tranche 2 shares, shares issued to
Directors (or nominees) of Tetratherix, are subject to shareholder approval at a general meeting of shareholders.
Details of the Share Purchase Plan
Tetratherix will also offer eligible shareholders the opportunity to participate in a non-underwritten share purchase
plan (SPP) to raise up to a further $2M (before costs). Under the SPP, eligible TTX shareholders, being
shareholders with registered addresses in Australia or New Zealand on TTX's register as at 7:00pm (Sydney
time) on 26 May 2026, being the record date (Eligible Shareholders), can apply for up to $30,000 worth of new
fully paid ordinary shares in the Company (SPP Shares) without incurring brokerage or other transaction costs.
The SPP Shares will be issued at $6, being the amount to be paid by institutional investors under the Placement.
The SPP offer period will be open on 4 June 2026 and is expected to close at 5:00pm (Sydney time) on 18 June
2026 (unless extended or closed earlier at the discretion of Tetratherix).
ASX RELEASE
28TH MAY 2026
2
Details of the Share Purchase Plan Continued
Further details of the SPP will be set out in the SPP Offer Booklet, which will be released to the ASX and made
available to eligible shareholders in Australia and New Zealand on or around 4 June 2026.
Given the SPP is capped at $2M, in the event of oversubscription, Tetratherix will scale back applications. Any
scale back will be applied on a pro rata basis, having regard to the applicant's shareholding at the record date and
will be conducted having regard to all applicable regulatory requirements.
Placement and SPP Investor Presentation
Please see the investor presentation attached to this announcement.
Joint Lead Managers
Barrenjoey Markets Pty Limited and Morgans Corporate Limited acted as joint lead managers to the Placement.
< ENDS >
This announcement was authorised for ASX release by the CEO.
For further information please contact:
Jacob Pfeffer
General Counsel | Company Secretary
+61 425 194 200
jacob.pfeffer@tetratherix.com
https://tetratherix.com/
Tetratherix
Growth Capital
Presentation
ASX: TTX
May 2026
Important Information & Disclaimer
This investor presentation (Presentation) is dated 26 May 2026 and has been prepared by Tetratherix Limited ACN 607 771 077 (Tetratherix or Company). By attending an investor presentation or briefing, or accepting, accessing or reviewing this Presentation, you acknowledge and agree to the terms set out below.
This Presentation has been prepared in relation to: (i) a placement of fully paid ordinary shares in Tetratherix (New Shares) to institutional investors under section 708A of Corporations Act as modified by ASIC Corporations (Disregarding Technical Relief) Instrument 2016/73 (Placement); and (ii)
a share purchase plan in accordance with ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 (SPP), (the Placement and SPP together, the Offer).
Summary information
This Presentation is for information purposes only and is a summary only. It should be read in conjunction with Tetratherix’s most recent financial report and Tetratherix’s other periodic and continuous disclosure information lodged with the Australian Securities Exchange (ASX), which are available at www.asx.com.au. The content of this Presentation is
provided as at the date of this Presentation (unless otherwise stated). Reliance should not be placed on information or opinions contained in this Presentation and, subject only to any legal obligation to do so, Tetratherix does not have any obligation to correct or update the content of this Presentation.
Certain market and industry data used in this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither Tetratherix nor its representatives have independently verified any such market or industry data provided by third parties or industry or general publications.
Not financial product advice or offer
This Presentation does not, and does not purport to, contain all information necessary to make an investment decision, is not intended as investment or financial product advice (nor tax, accounting or legal advice), must not be relied upon as such and does not and will not form any part of any contract or commitment for the acquisition of New shares. Any
decision to buy or sell securities or other products should be made only after seeking appropriate financial advice.
This Presentation is of a general nature and does not take into consideration the investment objectives, financial situation or particular needs of any particular investor.
Any investment decision should be made solely on the basis of your own enquiries. Before making an investment in Tetratherix, you should consider whether such an investment is appropriate to your particular investment objectives, financial situation or needs. Tetratherix is not licensed to provide financial product advice in respect of its shares.
This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law or any other law (and will not be lodged with the Australian Securities and Investments Commission (ASIC) or any other foreign regulator). This Presentation is not, and does not constitute, an invitation or offer of securities for subscription,
purchase or sale in any jurisdiction.
The distribution of this Presentation in jurisdictions outside Australia is restricted by law and you should observe any such restrictions, including those set forth in Appendix C of this Presentation. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. Refer to Appendix C of this Presentation for further details about
international offer restrictions.
This Presentation may not be distributed or released in the United States. The entitlements and the New shares have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (U.S. Securities Act), or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold, directly or indirectly, in the
United States, unless they have been registered under the U.S. Securities Act (which Tetratherix has no obligation to do or procure) or are offered or sold in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and any other applicable U.S. state securities laws.
The SPP booklet for the SPP will be available following its lodgement with ASX. Any eligible retail shareholder in Australia or New Zealand who wishes to participate in the SPP should consider the SPP booklet before deciding whether to apply under that offer.
Investment risk
An investment in Tetratherix shares is subject to known and unknown risks, some of which are beyond the control of Tetratherix and its directors. Tetratherix does not guarantee any particular rate of return or the performance of Tetratherix, nor does it guarantee any particular tax treatment. You should have regard to the risk factors outlined in Appendix B of
this Presentation when making your investment decision. Cooling off rights do not apply to the acquisition of New shares.
Financial information
All financial information in this Presentation is in Australian dollars ($ or $A) unless otherwise stated. This Presentation may contain certain pro forma financial information. Any such pro forma financial information provided in this Presentation is for illustrative purposes only and is not represented as being indicative of Tetratherix’s views on its, nor anyone else’s,
future financial position and/or performance. Any pro forma financial information has been prepared by Tetratherix in accordance with the measurement and recognition principles, but not the disclosure requirements, prescribed by the Australian Accounting Standards (AAS). In addition, the pro forma financial information in this Presentation does not purport to
be in compliance with Article 11 of Regulation S-X of the rules and regulations of the U.S. Securities and Exchange Commission, and such information does not purport to comply with Article 3-05 of Regulation S-X.
Investors should be aware that certain financial measures included in this Presentation are ‘non-IFRS financial information’ under ASIC Regulatory Guide 230: ‘Disclosing non-IFRS financial information’ published by ASIC and also ‘non-GAAP financial measures’ within the meaning of Regulation G under the U.S. Securities Exchange Act of 1934, as
amended, and are not recognised under AAS and International Financial Reporting Standards (IFRS). Such non-IFRS financial information/non-GAAP financial measures do not have a standardised meaning prescribed by AAS or IFRS. Therefore, the non-IFRS financial information may not be comparable to similarly titled measures presented by other
entities and should not be construed as an alternative to other financial measures determined in accordance with AAS or IFRS. Although Tetratherix believes these non-IFRS financial measures provide useful information to investors in measuring the financial performance and condition of its business, investors are cautioned not to place undue reliance on any
non-IFRS financial information/non-GAAP financial measures included in this Presentation.
Certain figures, amounts, percentages, estimates, calculations of value and fractions provided in this Presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this Presentation.
Past performance
Past performance, including past share price performance of Tetratherix and pro forma financial information given in this Presentation, is given for illustrative purposes only and should not be relied upon as (and is not) an indication of Tetratherix’s views on its future financial performance or condition. Past performance of Tetratherix cannot be relied upon as an
indicator of (and provides no guidance as to) the future performance of Tetratherix. Nothing contained in this Presentation nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee, whether as to the past, present or future.
Future performance and forward-looking statements
This Presentation contains certain “forward-looking statements”. The words “expect”, “anticipate”, “estimate”, “intend”, “believe”, “guidance”, “should”, “could”, “may”, “will”, “predict”, “plan” and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are
also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors that are beyond the control of Tetratherix, its directors and management. This
includes statements about market and industry trends, which are based on interpretations of current market conditions.
You are strongly cautioned not to place undue reliance on forward-looking statements, particularly in light of the current economic climate and geopolitical tensions.
Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. These
statements may assume the success of Tetratherix’s business strategies. The success of any of those strategies will be realised in the period for which the forward-looking statement may have been prepared or otherwise. Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or regulation, none of
Tetratherix, its representatives or advisers assumes any obligation to update these forward-looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Presentation. The forward-
looking statements are based on information available to Tetratherix as at the date of this Presentation. Except as required by law or regulation (including the ASX Listing Rules), none of Tetratherix, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or
assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.
Disclaimer
Barrenjoey Markets Pty Limited ABN 66 636 976 059 (Barrenjoey) and Morgans Corporate Limited (ABN 32 010 539 607) (Morgans) are acting as joint lead managers (JLMs) to the Placement. Each JLM and each of their respective related bodies corporate, shareholders or affiliates and their respective officers, directors, employees, affiliates, agents or
advisers have not authorised, permitted or caused the issue, lodgement, submission, dispatch or provision of this Presentation and do not make or purport to make any statement in this Presentation and there is no statement in this Presentation which is based on any statement by such persons. You agree that you have not relied on any statement made by
such persons in relation to the Offer and you further expressly disclaim that you are in a fiduciary relationship with any of them in relation to the Offer. To the maximum extent permitted by law, Tetratherix, each of the JLMs and each of their respective related bodies corporate and affiliates, and their respective officers, directors, employees, agents and advisers:
(I) disclaim all responsibility and liability (including, without limitation, any liability arising from fault, negligence or negligent misstatement) for any loss arising from this Presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this Presentation, and have not independently verified such information and take no
responsibility for any part of this Presentation or the Offer; (ii) disclaim any obligations or undertaking to release any updates or revisions to the information in this Presentation to reflect any change in expectations or assumptions; and (iii) do not make any representation or warranty, express or implied, as to the accuracy, reliability, completeness of the
information in this Presentation or that this Presentation contains all material information about Tetratherix or that a prospective investor or purchaser may require in evaluating a possible investment in Tetratherix or acquisition of shares in Tetratherix, or likelihood of fulfilment of any forward-looking statement or any event or results expressed or implied in any
forward-looking statement. You acknowledge and agree that determination of eligibility of investors for the purposes of the Offer is determined by reference to a number of matters, including legal requirements, logistical and registry constraints and the discretion of Tetratherix and the JLMs. Each of Tetratherix and the JLMs disclaim any duty or liability
(including for negligence) in respect of the determination, exercise or otherwise of that discretion, to the maximum extent permitted by law. Tetratherix and the JLMs (and their respective affiliates) may rely on information provided by and on behalf of investors in connection with managing and conducting the Offer and without having independently verified that
information, and do not assume any responsibility for the accuracy or completeness of that information. Each of the JLMs and their affiliates are full service financial institutions engaged in various activities, which may include trading, financial advisory, investment management, investment research, principal investment, hedging, market making, brokerage and
other financial and non-financial activities and services including for which they have received or may receive customary fees and expenses or other transaction consideration. In the course of these activities, each of the JLMs and their affiliates may at any time for their own account and for the accounts of their clients make or hold investments in equity
securities or other financial products of Tetratherix or its affiliates and receive customary fees and expenses or other transaction consideration in respect of such activities. The JLMs have received or expect to receive fees and reimbursement of expenses. This presentation is for corporate communication purposes only and is not intended as promotion or
advertising to any audience in any jurisdiction. This presentation may also contain statistical data and information based on independent sources, industry publications or other publicly available information. We have not independently verified the accuracy or completeness of such data and information. Accordingly, we make no representations as to the
accuracy or completeness of such data or information. You are cautioned not to give undue weight to such data.
Tetramatrix™ is the Tetratherix proprietary biomaterial platform utilised across three established franchises - bone regeneration, tissue spacing and tissue
healing - underpinned by a capital-light licensing and supply model
Core franchises remain on track and in line with the timelines outlined in the prospectus. Our Tegenix (dental) FDA 510k process remaining on track with
all TTX testing and reporting completed, submission and review process is well underway. TTX has one final third party report to submit upon receipt in the
coming weeks. Depending on FDA review timelines, this review could be complete as early as July but the company has no clarity on exact timelines
In March 2026, Tetratherix announced a fourth franchise - Precision Medicine - anchored initially on an exclusive R&D agreement with US precision health
company Superpower Health Inc, which will pay Tetratherix US$3m per annum in licence fees plus additional polymer sales revenue for up to 10 years,
making the new franchise immediately revenue-generating in FY26. Tetratherix has received the cash payment for the first year licencing fee and the first
polymer sale is imminent
Critically, the Precision Medicine franchise is entirely additive - it leverages the same Tetramatrix™ platform polymer (branded as STEPP) as the existing
franchises and has been developed in stealth over 5 years partially in collaboration with big-pharma leaders
Nine months post-IPO Tetratherix has delivered against key prospectus milestones on time and on budget, with a strong cash position of A$19.2m as at 31
March 2026 - funds raised at the IPO have been deployed as disclosed in the prospectus - Tetratherix is funded through to the start of FY28
Tetratherix is today announcing an equity raising to raise A$15m to fund incremental growth over and above the IPO strategic plan, the raise represents
the accelerated evolution of Tetratherix from an R&D entity to a commercial organisation
Executive Summary
Executive Summary
The evolving dynamics of the global healthcare system are demanding innovative and cost-effective biomaterials
Trends in healthcare delivery
Patients are increasingly demanding higher quality of care with a
particular focus on reducing recovery times and lower risk of
complications (e.g. infection, blood loss, pain) - which is also a driver
of increasing healthcare costs for patients and payers
Rising patient expectations
Increasing global healthcare spending and demand for healthcare
services is necessitating investment in cost-effective tools and
treatments, including those that can be delivered outside a traditional
hospital setting, to minimise burden on the healthcare system
Need for cost-effective, decentralised care
Why does the world need Tetratherix?
Introduction
These numbers are forecast to double
over the next 10 years
70m
Estimated 70 million US outpatient
procedures per year and increasing by
>6%
60% Nearly 60% of outpatients
are operated on in ASCs
2X
Orthopaedic, ophthalmology, urology
and neuro/pain are the main segments
being disrupted
Our Tetramatrix™ platform is best positioned to address the clinical demands that are central to the evolution
Minimally invasive
delivery
Water-based solution
injected through fine
gauge needle
Safe,
biocompatible
and bioresorbable
No foreign body reaction
upon application
Low cost, scalable
production
Non-labour intensive, low
cost and readily available
materials
Seamlessly
integrated into
existing workflows
No additional equipment
required
How does Tetramatrix™ help facilitate this shift?
Introduction
Tetramatrix
A biomaterial platform built with unique polymer programming akin to “medical Lego ” to
form implantable products to solve a wide range of clinical problems. The platform has built
products for 7 anatomical sites with 3 chemical entities derived from the core technology.
Intelligent
Modular
Biomimetic
Safe
The matrix has similar water content and mechanical properties to
natural tissue, and therefore is impervious to the body, helping heal
injuries or physically manipulating the body during surgical interventions.
Standard
of
care
Treated
with
our
platform
Inflammatory Fibrovascular (IFV)
Tissue ingrowth
Human Histological Evaluation
Tetramatrix™ platform technology is the world’s first biostealth fluid matrix
A decade of polymer programming has led to an ideal consistency & physical performance.
The material is an injectable fluid to avoid causing damage to the body during its application.
Using physiological temperature, material transitions into a 3D matrix.
Introduction
Due to the unique polymer programming of the material, once the matrix serves its
purpose, the material gradually and safely bioresorbs in the body with no impact locally or
systemically. Biocompatibility data from multiple clinical trials show no impact to internal organs
or blood markers.
Transparent
Opaque
12 weeks
Structure
Stability
5 minutes
Long-bone
Biomechanics
Eye tissue
Preclinical studies (equivalent to 5 litre product administration)
No effects on blood markers for internal functions of
liver, kidney and spleen
Fully resorbed and excreted from the body
Derived medical devices from the Tetramatrix™ platform technology span multiple large
franchises and significant near-term commercial opportunities
Franchises
Tissue Healing
Tissue Spacing
Bone Regeneration
Bone graft extender for
dental surgeries
Flowable bone graft
extender for orthopaedic
applications
Prostate Spacer for
radiation therapy
Spacer during
cataract surgeries
Intraoperative solution to reduce scar
formation after surgeries
An initial addressable
combined market of
$US6.8B*
$US6.8B
Same core technology,
same material and
interchangeable dataset
Tissue
Healing
Tissue
Spacing
Bone
Regeneration
Precision
Medicine
*TAM Defined by 3 initial franchises only
Expansion by Design: Transitioning from Three Pillars to a Four-Node Ecosystem
Different clinical needs. Different market segments. Single Tetramatrix platform technology.
TM
The Tetramatrix biomaterial is our core ‘platform’ technology. We have completed the
foundational safety, efficacy and manufacturing work which is transferable across different clinical
applications of the platform.
We will license the IP in a specific field to a leader in the segment. These partners complete the
“final 20%” to turn the application into a clinical product. We will then manufacture the product and
supply at attractive unit economics to our industry leading partners who distribute it through their
sales channels.
We will enjoy periodic milestone payments as well as a steady flow of income from product supply
- a dual revenue source brings the best of both worlds.
Think of us like a software platform business...
Commercial model
Supply of
product at
scale
Licensing &
Milestone
Payments
1 2
Our Partner Matrix - How We Choose
Hunger &
Strategic
Alignment
Innovation &
Collaboration
Culture
Global Scale &
Infrastructure
Many years of
Due Diligence
required from
both parties
All three
requirements
need to be
satisfied
A capital light model with compounding revenue
While we build our own production and R&D infrastructure, we avoid committing
capital on establishing multiple sales & distribution networks by utilising the
capabilities of our partners’ established teams.
Importantly, we operate in unison with our partners. Our high margin revenue
compounds over time by adding new partnerships and launching new products.
Similar to a ‘build-to-buy’ model, we partner differently to, and at earlier stages than,
traditional medtech companies. Therefore, our return profile is different and not built
on expectations of an eventual acquisition.
Avoided Sales &
Marketing Cost by
using partners’ in-
market infrastructure
Design Proof of Concept
Clinical
Validation
Regulatory
Approval
Go-to-Market
Income
Cost
Plateaued Cost
In TTX Model
Commercial model
This unique and attractive model is enabled by:
A platform technology that allows parallel developments
Advanced manufacturing with economies of scale
Partnerships with leading players who are motivated to
sell over a long time
A patient & deliberate strategy
An operational moat with IP Leadership built on a global R&D infrastructure. This sets us apart.
Supported by complete IP coverage
Patent stack with 36 granted patents from 9 families of patent,
extending to 2044 & beyond and fully owned by Tetratherix
Introduction
61%
R&D
39%
R&D
39%
*R&D includes specific projects,
directly attributable staff,
laboratory costs, trademarks and
patents
Bone Regeneration
$A2.0m
Tissue Healing
$A0.7m
Tissue Spacing $A0.1m
Pipeline $A0.3m
FDA regulatory studies x 2
(Tegenix and TegenEOS)
Clinical trial for scar
prevention (TetraDerm)
Preclinical in AU/US
Tutelix clinical trial + BioOptix
preclinical
Overview of the
Equity Raising
ASX: TTX
Summary of the Equity Raising
Offer size, structure and underwriting
The Company is undertaking an institutional placement to raise A$15m via the issue of ~2.5 million new fully paid ordinary shares (New Shares) utilising their
placement capacity under ASX listing rule 7.1 (Placement)
Placement size represents approximately ~4.9% of the Company’s existing ordinary shares on issue
In addition to the Placement, the Company will also be undertaking a share purchase plan to eligible shareholders to raise up to A$2 million (SPP)
The Placement and the SPP are not underwritten
Placement pricing
The Placement and SPP will be conducted at A$6 per New Share (Offer Price), representing a:
14.0% discount to the last close price of A$6.98 per New Share on 25 May 2026
10.8% discount to the 5-day volume weighted average price of A$6.72
Use of proceeds
Proceeds will be used to scale manufacturing capacity, drive commercialisation through go-to-market partnerships and customer success, and accelerate digitalisation
across R&D and clinical programs
Ranking New Shares issued under the Placement and SPP will rank equally with existing shares in the Company from their respective issue dates
Share purchase plan
Eligible shareholders of the Company with a registered address in Australia and New Zealand will be invited to apply for up to A$30,000 of New Shares free of any
brokerage, commission and transaction costs
The SPP may raise up to A$2m
T
Share your feedback
Discover